Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.57 |
| ▸ | VCP | P55072 | 3/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241242 | 1.00 | FBP1 (0.57) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL2285892 | 0.87 | FBP1 (0.67) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL2285894 | 0.87 | FBP1 (0.67) | FBP1VCPEGFRABL1ABL2 | |
| SCHEMBL5924031 | 0.87 | FBP1 (0.67) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL5924030 | 0.87 | FBP1 (0.67) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL23684551 | 0.75 | FBP1 (0.60) | FBP1VCPEGFRALDH1A1MAPT | |
| SCHEMBL17048998 | 0.74 | HSP90AA1 (0.61) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL17048996 | 0.74 | HSP90AA1 (0.61) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL20177890 | 0.74 | VCP (0.53) | FBP1VCPTERTEGFRABL1 | |
| SCHEMBL807974 | 0.74 | VCP (0.66) | FBP1VCPTERTEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025104443-A1 | INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | FBP1 2487/4885VCP 1344/4885TERT 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.